



Joint position statement on the use of generic Eltrombopag


From October 2025, the UK will have access to generic eltrombopag. Eltrombopag is one of three thrombopoietin receptor agonists (TPO RA) that are licenced treatments for immune thrombocytopenia (ITP).

The alternatives are romiplostim and avatrombopag. While these treatments are not identical, their effectiveness is broadly similar and greater use of generic eltrombopag will result in a substantial, multi-million-pound, cost saving to the NHS.

Recommendations for use of TPO RA in patients with ITP:

- For ITP patients requiring a TPO RA, the preferred initial TPO RA would be generic eltrombopag.
- If there are issues of tolerability with generic eltrombopag, measures to enable tolerability should be considered before moving onto subsequent TPO RA
- Patients who are intolerant or unresponsive to generic eltrombopag may be switched to an alternative TPO RA.
- Patients currently stabilised/established on a different TPO RA should continue with this treatment
- Patients currently receiving Revolade (branded eltrombopag) should be switched to generic eltrombopag, although sufficient time should be allowed for staff training and support for this process.
- TPO RA should be accessible as second line treatment after failure of first line treatments (e.g. corticosteroids, intravenous immunoglobulins) without time restriction
- Systems should consider investing in ITP clinical nurse support to optimise patient care and maximise efficiency opportunities presented by generic eltrombopag

Recommended pathway:



*Dietary restrictions and monitoring requirements apply equally to Revolade and generic eltrombopag

Dr. Quentin Hill
Chair, UK ITP Forum

Mervyn Morgan
CEO, ITP Support Association

